43.65
0.92%
0.40
プレマーケット:
42.49
-1.16
-2.66%
前日終値:
$43.25
開ける:
$42.82
24時間の取引高:
666.09K
Relative Volume:
0.54
時価総額:
$5.20B
収益:
$10.60M
当期純損益:
$-252.45M
株価収益率:
-14.08
EPS:
-3.1
ネットキャッシュフロー:
$-158.91M
1週間 パフォーマンス:
-16.86%
1か月 パフォーマンス:
-13.48%
6か月 パフォーマンス:
+49.28%
1年 パフォーマンス:
+631.16%
Avidity Biosciences Inc Stock (RNA) Company Profile
名前
Avidity Biosciences Inc
セクター
電話
858-401-7900
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
RNA | 43.65 | 5.20B | 10.60M | -252.45M | -158.91M | -3.10 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-09-24 | 開始されました | Goldman | Buy |
2024-08-28 | 開始されました | Barclays | Overweight |
2024-05-03 | 開始されました | BofA Securities | Buy |
2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
2022-07-12 | 開始されました | Raymond James | Strong Buy |
2021-09-07 | 開始されました | Evercore ISI | Outperform |
2021-06-17 | 開始されました | Needham | Buy |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2020-07-07 | 開始されました | Cowen | Outperform |
2020-07-07 | 開始されました | Credit Suisse | Outperform |
2020-07-07 | 開始されました | SVB Leerink | Outperform |
2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Avidity Biosciences Inc (RNA) 最新ニュース
Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN
Mutual of America Capital Management LLC Cuts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat
Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat
RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences unveils new cardiology development candidates - BioWorld Online
RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance
US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - Yahoo! Voices
Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow
Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com
Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha
Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com
Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks
Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PR Newswire
Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance
431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat
Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India
Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada
Wellington Management Group LLP's Strategic Acquisition in Avidi - GuruFocus.com
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences Reports Strong Q3 Progress and Outlook - TipRanks
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Avidity Bio's DMD Drug Shows 25% Dystrophin Boost; Reports $1.6B Cash Position | RNA Stock News - StockTitan
Avidity Biosciences (NASDAQ:RNA) Trading Up 6.5%What's Next? - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused o - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 – Company AnnouncementFT.com - Financial Times
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada
Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada
Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com
Avidity Biosciences Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
Avidity Biosciences Inc (RNA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
McCarthy Teresa | Chief Human Resources Officer |
Nov 18 '24 |
Sale |
41.14 |
25,000 |
1,028,520 |
94,018 |
LEVIN ARTHUR A | Director |
Nov 19 '24 |
Option Exercise |
1.24 |
3,323 |
4,121 |
18,153 |
LEVIN ARTHUR A | Director |
Nov 19 '24 |
Sale |
42.12 |
3,323 |
139,973 |
14,830 |
MacLean Michael F | Chief Financial Officer |
Nov 06 '24 |
Option Exercise |
8.43 |
79,057 |
666,064 |
159,275 |
MacLean Michael F | Chief Financial Officer |
Nov 06 '24 |
Sale |
45.56 |
106,319 |
4,843,979 |
94,093 |
大文字化:
|
ボリューム (24 時間):